CN101778935A - 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 - Google Patents
用于进行间充质干细胞(msc)生长调节的低硬度凝胶 Download PDFInfo
- Publication number
- CN101778935A CN101778935A CN200880102208A CN200880102208A CN101778935A CN 101778935 A CN101778935 A CN 101778935A CN 200880102208 A CN200880102208 A CN 200880102208A CN 200880102208 A CN200880102208 A CN 200880102208A CN 101778935 A CN101778935 A CN 101778935A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cell
- another embodiment
- gel
- mescenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000012010 growth Effects 0.000 title claims description 38
- 239000000499 gel Substances 0.000 title abstract description 296
- 238000000034 method Methods 0.000 claims abstract description 154
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 443
- 210000000130 stem cell Anatomy 0.000 claims description 384
- 239000011159 matrix material Substances 0.000 claims description 146
- 230000001939 inductive effect Effects 0.000 claims description 97
- 239000000463 material Substances 0.000 claims description 96
- 230000004069 differentiation Effects 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 78
- 210000004504 adult stem cell Anatomy 0.000 claims description 61
- 239000000835 fiber Substances 0.000 claims description 55
- 239000000126 substance Substances 0.000 claims description 46
- 210000002966 serum Anatomy 0.000 claims description 43
- 230000035755 proliferation Effects 0.000 claims description 39
- 210000001789 adipocyte Anatomy 0.000 claims description 38
- 230000000284 resting effect Effects 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 229920001436 collagen Polymers 0.000 claims description 30
- 102000008186 Collagen Human genes 0.000 claims description 28
- 108010035532 Collagen Proteins 0.000 claims description 28
- 102000002734 Collagen Type VI Human genes 0.000 claims description 28
- 108010043741 Collagen Type VI Proteins 0.000 claims description 28
- 108010049003 Fibrinogen Proteins 0.000 claims description 28
- 102000008946 Fibrinogen Human genes 0.000 claims description 28
- 229940012952 fibrinogen Drugs 0.000 claims description 28
- 230000004071 biological effect Effects 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 18
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 18
- 210000000988 bone and bone Anatomy 0.000 claims description 16
- 230000000050 nutritive effect Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000006495 integrins Human genes 0.000 claims description 12
- 108010044426 integrins Proteins 0.000 claims description 12
- 230000000638 stimulation Effects 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 8
- 239000003630 growth substance Substances 0.000 claims description 7
- 210000002027 skeletal muscle Anatomy 0.000 claims description 7
- 102000019034 Chemokines Human genes 0.000 claims description 5
- 108010012236 Chemokines Proteins 0.000 claims description 5
- 210000003074 dental pulp Anatomy 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 210000004165 myocardium Anatomy 0.000 claims description 5
- 210000003954 umbilical cord Anatomy 0.000 claims description 5
- 210000001612 chondrocyte Anatomy 0.000 claims description 4
- 210000000107 myocyte Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 239000012888 bovine serum Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 description 112
- 210000001519 tissue Anatomy 0.000 description 107
- 238000012258 culturing Methods 0.000 description 78
- 229920002401 polyacrylamide Polymers 0.000 description 51
- 230000022131 cell cycle Effects 0.000 description 44
- 239000010410 layer Substances 0.000 description 37
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 36
- 238000012360 testing method Methods 0.000 description 36
- 230000004132 lipogenesis Effects 0.000 description 33
- 239000000243 solution Substances 0.000 description 32
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 30
- 239000011521 glass Substances 0.000 description 30
- 239000001963 growth medium Substances 0.000 description 30
- 239000006059 cover glass Substances 0.000 description 29
- 230000006870 function Effects 0.000 description 29
- 239000003112 inhibitor Substances 0.000 description 28
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 239000003446 ligand Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 21
- 108010073385 Fibrin Proteins 0.000 description 20
- 102000009123 Fibrin Human genes 0.000 description 20
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 20
- 229950003499 fibrin Drugs 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 20
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000010008 shearing Methods 0.000 description 20
- 108060005987 Kallikrein Proteins 0.000 description 19
- 102000001399 Kallikrein Human genes 0.000 description 19
- 102000042463 Rho family Human genes 0.000 description 19
- 108091078243 Rho family Proteins 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 18
- 238000003860 storage Methods 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- 230000008878 coupling Effects 0.000 description 16
- 238000010168 coupling process Methods 0.000 description 16
- 238000005859 coupling reaction Methods 0.000 description 16
- 238000004043 dyeing Methods 0.000 description 16
- 230000006698 induction Effects 0.000 description 15
- 210000003632 microfilament Anatomy 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 244000309466 calf Species 0.000 description 14
- 210000004500 stellate cell Anatomy 0.000 description 14
- 101100148273 Chlorobaculum tepidum (strain ATCC 49652 / DSM 12025 / NBRC 103806 / TLS) rub3 gene Proteins 0.000 description 13
- 101150086350 rub gene Proteins 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 230000003534 oscillatory effect Effects 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000006116 polymerization reaction Methods 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 108010067306 Fibronectins Proteins 0.000 description 10
- 102000016359 Fibronectins Human genes 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000010998 test method Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 108010016731 PPAR gamma Proteins 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 108091005804 Peptidases Proteins 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 210000003518 stress fiber Anatomy 0.000 description 9
- 239000002753 trypsin inhibitor Substances 0.000 description 9
- 108010043137 Actomyosin Proteins 0.000 description 8
- 102000000536 PPAR gamma Human genes 0.000 description 8
- 229940122618 Trypsin inhibitor Drugs 0.000 description 8
- 101710162629 Trypsin inhibitor Proteins 0.000 description 8
- 210000003754 fetus Anatomy 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 230000013011 mating Effects 0.000 description 6
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 6
- PBWRQSSISZQGFM-UHFFFAOYSA-N n'-hydroxybutanediamide;prop-2-enoic acid Chemical compound OC(=O)C=C.NC(=O)CCC(=O)NO PBWRQSSISZQGFM-UHFFFAOYSA-N 0.000 description 6
- 210000002824 peroxisome Anatomy 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- -1 vinylformic acid N-hydroxy-succinamide ester Chemical class 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 5
- 241000581650 Ivesia Species 0.000 description 5
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 5
- 108010017842 Telomerase Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000019688 fish Nutrition 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 4
- 239000004160 Ammonium persulphate Substances 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 4
- 102000011068 Cdc42 Human genes 0.000 description 4
- 108050001278 Cdc42 Proteins 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
- 235000019395 ammonium persulphate Nutrition 0.000 description 4
- 210000003995 blood forming stem cell Anatomy 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000000518 rheometry Methods 0.000 description 4
- 230000008698 shear stress Effects 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000017105 transposition Effects 0.000 description 4
- 229940108519 trasylol Drugs 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 241000233855 Orchidaceae Species 0.000 description 3
- 108010009711 Phalloidine Proteins 0.000 description 3
- 102100035124 Rhotekin Human genes 0.000 description 3
- 101710122991 Rhotekin Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 210000004292 cytoskeleton Anatomy 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical group CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 230000004072 osteoblast differentiation Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- OCQZXMCGTAWGEQ-UHFFFAOYSA-N prop-2-enamide;n-[(prop-2-enoylamino)methyl]prop-2-enamide Chemical compound NC(=O)C=C.C=CC(=O)NCNC(=O)C=C OCQZXMCGTAWGEQ-UHFFFAOYSA-N 0.000 description 3
- 238000010379 pull-down assay Methods 0.000 description 3
- 238000007586 pull-out test Methods 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- UPNUQQDXHCUWSG-UHFFFAOYSA-N 1-[6-(4-azido-2-nitroanilino)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O UPNUQQDXHCUWSG-UHFFFAOYSA-N 0.000 description 2
- JKYKXTRKURYNGW-UHFFFAOYSA-N 3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(O)=C(O)C(S(O)(=O)=O)=C2 JKYKXTRKURYNGW-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 102000008847 Serpin Human genes 0.000 description 2
- 108050000761 Serpin Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 210000002514 epidermal stem cell Anatomy 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001650 focal adhesion Anatomy 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 210000000514 hepatopancreas Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000001665 muscle stem cell Anatomy 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- OAHKWDDSKCRNFE-UHFFFAOYSA-N phenylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1=CC=CC=C1 OAHKWDDSKCRNFE-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical group FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- REHCIRYRMZFFJW-UHFFFAOYSA-N C1(=CC=CC=C1)CCC(C)=O.N Chemical compound C1(=CC=CC=C1)CCC(C)=O.N REHCIRYRMZFFJW-UHFFFAOYSA-N 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IFPVZZFGBQUVJE-UHFFFAOYSA-N Cl.NCCCCCC(C)=O.N Chemical compound Cl.NCCCCCC(C)=O.N IFPVZZFGBQUVJE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010077781 F-actin-binding proteins Proteins 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical group C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical group NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GDXWHFPKFUYWBE-UHFFFAOYSA-N [F].Cl Chemical compound [F].Cl GDXWHFPKFUYWBE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical group [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- JGUQDUKBUKFFRO-CIIODKQPSA-N dimethylglyoxime Chemical compound O/N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-CIIODKQPSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010036236 extracellular matrix receptor Proteins 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical group OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical group Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 150000004780 naphthols Chemical class 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000002642 osteogeneic effect Effects 0.000 description 1
- 238000009401 outcrossing Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001624 pentamidine isethionate Drugs 0.000 description 1
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical group OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical group OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Investigating Strength Of Materials By Application Of Mechanical Stress (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
物种 | 组织 | 弹性(帕)(平均值+/-标准偏差) |
牛 | 骨髓 | 220+/-50 |
大鼠 | 皮下脂肪 | 160+/-70 |
大鼠 | 内脏脂肪 | 130+/-70 |
大鼠 | 肝脏 | 403+/-28 |
大鼠 | 骨骼肌 | 2251+/-166 |
条目 | 象征符号 | 定义 | 所提供的信息 |
复数模量 | G* | [(G’)2+(G”)2]0.6 | 全部的粘弹性特征 |
条目 | 象征符号 | 定义 | 所提供的信息 |
弹性模量贮能模量 | G’ | G*cosδ | 每个形变周期中所贮存的能量;固体样行为或者弹性行为 |
粘性模量损失模量 | G” | G*sinδ | 每个形变周期中所消散的能量;流体样行为或者粘性行为 |
复数粘度 | η* | G*/ω | 粘弹性流体 |
组织 | 硬度(帕) |
牛骨髓 | 225+/-25 |
大鼠皮下脂肪 | 157+/-36 |
大鼠内脏脂肪 | 130+/-40 |
大鼠肝脏 | 403+/-28 |
大鼠骨骼肌 | 2251+/-166 |
物种 | 牛 | 大鼠 | 大鼠 |
组织 | 骨髓 | 内脏脂肪 | 皮下脂肪 |
弹性(平均值+/-标准偏差) | 220+/-50帕 | 130+/-70帕 | 160+/-70帕 |
Claims (28)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610865534.XA CN106978393A (zh) | 2007-06-29 | 2008-06-30 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92948907P | 2007-06-29 | 2007-06-29 | |
US92948707P | 2007-06-29 | 2007-06-29 | |
US60/929,487 | 2007-06-29 | ||
US60/929,489 | 2007-06-29 | ||
US96007007P | 2007-09-14 | 2007-09-14 | |
US60/960,070 | 2007-09-14 | ||
PCT/US2008/008120 WO2009005770A1 (en) | 2007-06-29 | 2008-06-30 | Low rigidity gels for msc growth modulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610865534.XA Division CN106978393A (zh) | 2007-06-29 | 2008-06-30 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101778935A true CN101778935A (zh) | 2010-07-14 |
CN101778935B CN101778935B (zh) | 2016-10-26 |
Family
ID=40226420
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610865534.XA Pending CN106978393A (zh) | 2007-06-29 | 2008-06-30 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
CN200880102208.7A Expired - Fee Related CN101778935B (zh) | 2007-06-29 | 2008-06-30 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610865534.XA Pending CN106978393A (zh) | 2007-06-29 | 2008-06-30 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10214720B2 (zh) |
EP (2) | EP3034606A1 (zh) |
JP (3) | JP5737936B2 (zh) |
CN (2) | CN106978393A (zh) |
CA (1) | CA2691790C (zh) |
DK (1) | DK2173864T3 (zh) |
HK (2) | HK1219984A1 (zh) |
WO (1) | WO2009005770A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107922921A (zh) * | 2015-07-22 | 2018-04-17 | 英文提亚生命科学有限公司 | 3d打印组织培养模型的方法 |
CN108159499A (zh) * | 2017-12-06 | 2018-06-15 | 广西医科大学 | 一种复合凝胶及其制备方法和应用 |
CN113993528A (zh) * | 2019-04-10 | 2022-01-28 | 千纸鹤治疗公司 | 类生体组织结构体的制造方法 |
CN114525249A (zh) * | 2022-03-31 | 2022-05-24 | 广西大学 | 一种用于分离牛肌肉干细胞的肌肉组织提取方法及其应用 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2173859B1 (en) * | 2007-06-29 | 2016-05-11 | Makoto Funaki | Soft gel systems in modulating stem cell development |
CN106978393A (zh) | 2007-06-29 | 2017-07-25 | 船木真理 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
US8470308B2 (en) * | 2009-01-03 | 2013-06-25 | Ray C. Wasielewski | Enhanced medical implant comprising disrupted tooth pulp and tooth particles |
US10328103B2 (en) | 2009-01-03 | 2019-06-25 | Ray C. Wasielewski | Medical treatment composition comprising mammalian dental pulp stem cells |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
JP5360663B2 (ja) * | 2010-06-29 | 2013-12-04 | 国立大学法人徳島大学 | 培養脂肪細胞 |
US11007528B2 (en) | 2010-10-08 | 2021-05-18 | Cellanyx Diagnostics, Llc | Systems, methods and devices for measuring growth/oncogenic and migration/metastatic potential |
CA2814067A1 (en) * | 2010-10-08 | 2012-04-12 | Ashok C. Chander | Systems, methods, and devices for measuring growth/oncogenic potential and migration/metastatic potential |
WO2014058080A1 (ja) * | 2012-11-30 | 2014-04-17 | 独立行政法人理化学研究所 | 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット |
CN104046589B (zh) * | 2013-03-11 | 2016-09-14 | 中国科学院大连化学物理研究所 | 一种细胞共培养诱导干细胞体外定向分化的方法 |
MX2016001247A (es) | 2013-07-30 | 2016-08-17 | Musculoskeletal Transplant Foundation | Matrices derivadas de tejido suave acelular y metodos para preparar las mismas. |
EP3098306A4 (en) | 2014-01-23 | 2017-07-26 | Nissan Chemical Industries, Ltd. | Undifferentiated maintenance culture material |
EP3297694A1 (en) | 2015-05-21 | 2018-03-28 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US20210196646A1 (en) * | 2018-08-15 | 2021-07-01 | Wake Forest University Health Sciences | Improved formulations for pancreatic islet encapsulation |
JP7432808B2 (ja) | 2019-05-17 | 2024-02-19 | 東ソー株式会社 | 細胞分化方法 |
WO2022045201A1 (ja) * | 2020-08-27 | 2022-03-03 | 株式会社カネカ | 接着性細胞を組織から効率的に製造する方法 |
EP4238985A4 (en) * | 2020-10-29 | 2024-05-08 | Univ Osaka | METHOD FOR FREEZING A CELL STRUCTURE |
US20230000954A1 (en) * | 2021-07-02 | 2023-01-05 | Combangio, Inc. | Processes for making and using a cellular fibronectin composition |
CN113846054B (zh) * | 2021-09-23 | 2023-05-16 | 四川大学 | 将成纤维细胞直接重编程为成骨细胞的基质材料及制备方法和重编程方法 |
CA3234969A1 (en) * | 2021-10-12 | 2023-04-20 | Makoto Funaki | Anti-aging composition using mesenchymal stem cells and methods thereof |
CN116693931B (zh) * | 2023-07-25 | 2023-10-17 | 中山大学 | 一种超结构多孔湿性粘合水凝胶及其制备方法与应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020168718A1 (en) | 1997-04-03 | 2002-11-14 | California Institute Of Technology | Enzyme-mediated modification of fibrin for tissue engineering |
US6991794B1 (en) * | 1997-06-24 | 2006-01-31 | Imclone Systems Incorporated | Progenitor cell preservation factors and methods for and products of their use |
WO1999056759A1 (en) | 1998-05-07 | 1999-11-11 | University Of South Florida | Bone marrow cells as a source of neurons for brain and spinal cord repair |
AU2001247880A1 (en) * | 2000-03-28 | 2001-10-08 | University Of Iowa Research Foundation | Methods to prepare and use epidermal stem cells |
US6861255B1 (en) | 2001-07-18 | 2005-03-01 | Sea Run Holdings, Inc. | Method of using fish plasma components for tissue culture |
EP1403304B1 (en) * | 2001-05-30 | 2008-08-27 | Keiichi Miyamoto | Crosslinked elastin and processes for its production |
CA2507581A1 (en) * | 2002-12-06 | 2004-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Protection of stem cells from cytotoxic agents by modulation of .beta.-catenin signaling pathways |
US20050058687A1 (en) | 2003-09-12 | 2005-03-17 | Becton, Dickinson And Company | Covalently attached collagen VI for cell attachment and proliferation |
AU2005210668A1 (en) | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
CA2603116A1 (en) * | 2005-03-29 | 2006-10-05 | The Regents Of The University Of California | Controlling stem cell destiny with tunable network |
US20070065415A1 (en) | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
JP2007116926A (ja) | 2005-10-25 | 2007-05-17 | Reprocell Inc | 体外における幹細胞の維持と純化に関する方法、組成物およびシステム |
US20070190646A1 (en) | 2006-02-10 | 2007-08-16 | The Trustees Of The University Of Pennsylvania | Regulating stem cell differentiation by controlling matrix elasticity |
EP2173859B1 (en) * | 2007-06-29 | 2016-05-11 | Makoto Funaki | Soft gel systems in modulating stem cell development |
CN106978393A (zh) * | 2007-06-29 | 2017-07-25 | 船木真理 | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 |
-
2008
- 2008-06-30 CN CN201610865534.XA patent/CN106978393A/zh active Pending
- 2008-06-30 CA CA2691790A patent/CA2691790C/en active Active
- 2008-06-30 JP JP2010514846A patent/JP5737936B2/ja active Active
- 2008-06-30 US US12/452,281 patent/US10214720B2/en active Active
- 2008-06-30 DK DK08779877.3T patent/DK2173864T3/en active
- 2008-06-30 WO PCT/US2008/008120 patent/WO2009005770A1/en active Application Filing
- 2008-06-30 EP EP15196849.2A patent/EP3034606A1/en not_active Withdrawn
- 2008-06-30 EP EP08779877.3A patent/EP2173864B1/en active Active
- 2008-06-30 CN CN200880102208.7A patent/CN101778935B/zh not_active Expired - Fee Related
-
2010
- 2010-10-12 HK HK16108073.5A patent/HK1219984A1/zh unknown
- 2010-10-12 HK HK10109630.5A patent/HK1143604A1/zh not_active IP Right Cessation
-
2014
- 2014-10-31 JP JP2014222238A patent/JP6251152B2/ja active Active
-
2017
- 2017-08-23 JP JP2017159904A patent/JP2018019703A/ja active Pending
-
2019
- 2019-01-25 US US16/258,269 patent/US20190225935A1/en active Pending
Non-Patent Citations (2)
Title |
---|
ADAM J. ENGLER ECT.AL: "Matrix elasticity directs stem cell lineage specification", 《CELL》 * |
PO-YANG CHEN ECT.AL: "Hyaluronan preserves the proliferation and differentiation potentials of long-term cultured murine adipose-derived stromal cells", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107922921A (zh) * | 2015-07-22 | 2018-04-17 | 英文提亚生命科学有限公司 | 3d打印组织培养模型的方法 |
CN107922921B (zh) * | 2015-07-22 | 2021-06-08 | 英文提亚生命科学有限公司 | 3d打印组织培养模型的方法 |
CN108159499A (zh) * | 2017-12-06 | 2018-06-15 | 广西医科大学 | 一种复合凝胶及其制备方法和应用 |
CN113993528A (zh) * | 2019-04-10 | 2022-01-28 | 千纸鹤治疗公司 | 类生体组织结构体的制造方法 |
CN114525249A (zh) * | 2022-03-31 | 2022-05-24 | 广西大学 | 一种用于分离牛肌肉干细胞的肌肉组织提取方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2009005770A1 (en) | 2009-01-08 |
US10214720B2 (en) | 2019-02-26 |
EP2173864B1 (en) | 2016-05-11 |
JP2010532167A (ja) | 2010-10-07 |
EP2173864A4 (en) | 2011-09-14 |
EP2173864A1 (en) | 2010-04-14 |
JP2015042184A (ja) | 2015-03-05 |
DK2173864T3 (en) | 2016-08-22 |
US20190225935A1 (en) | 2019-07-25 |
CN101778935B (zh) | 2016-10-26 |
JP5737936B2 (ja) | 2015-06-17 |
US20110177593A1 (en) | 2011-07-21 |
JP6251152B2 (ja) | 2017-12-20 |
CN106978393A (zh) | 2017-07-25 |
HK1143604A1 (zh) | 2011-01-07 |
HK1219984A1 (zh) | 2017-04-21 |
EP3034606A1 (en) | 2016-06-22 |
CA2691790C (en) | 2017-05-02 |
JP2018019703A (ja) | 2018-02-08 |
CA2691790A1 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101778935A (zh) | 用于进行间充质干细胞(msc)生长调节的低硬度凝胶 | |
CN101855337A (zh) | 用于进行干细胞调节的软凝胶*** | |
JP2010532167A5 (zh) | ||
JP2010532166A5 (zh) | ||
Lee et al. | Effects of uniaxial cyclic strain on adipose-derived stem cell morphology, proliferation, and differentiation | |
CN104582711B (zh) | 诱导心肌梗塞的修复再生的多能性干细胞 | |
CN105209607A (zh) | 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物 | |
WO2005007233A2 (en) | Application of electrical stimulation for functional tissue engineering in vitro and in vivo | |
CN105112357A (zh) | 来源于胎盘的贴壁细胞及其在疾病治疗中的应用 | |
RU2620947C2 (ru) | Биосинтетические системы проксимального канальца и способы использования | |
CN102884177B (zh) | Cd49f通过pi3k/akt/gsk3途径促进成体干细胞的增殖、专能性和重编程 | |
Naujok et al. | Effect of substrate rigidity in tissue culture on the function of insulin‐secreting INS‐1E cells | |
CN108601799A (zh) | 从年长细胞群中富集和扩增高潜能人间充质干细胞 | |
Seidel et al. | Migratory abilities of different vascular cells from the tunica media of canine vessels | |
CN108138139A (zh) | 用于培养细胞的装置、***和方法 | |
ES2577714T3 (es) | Geles de baja rigidez para la modulación del crecimiento de MSC | |
Fujii et al. | Chicken egg yolk-supplemented medium and the serum-free growth of normal mammalian cells | |
CN112771150B (zh) | 包含含有天然油的微胶囊的细胞培养用载体 | |
Curtis | Investigation of the Biochemical and Mechanical Cues Influencing Breast Cancer Metastasis to Trabecular Bone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: FUNAKI MAKOTO Free format text: FORMER OWNER: UNIVERSITY OF PENNSYLVANIA COUNCIL Effective date: 20100813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100813 Address after: American Pennsylvania Applicant after: Funaki Makoto Address before: American Pennsylvania Applicant before: The Trustees of The University of Pennsylvania |
|
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Funaki Makoto Inventor after: J. Wenir Inventor before: Funaki Makoto |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: FUNAKI MAKOTO TO: FUNAKI MAKOTO J. WINNERL |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1145854 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1145854 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161026 Termination date: 20170630 |